Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling

Fig. 1

Sirt6 expressions were upregulated and correlated with adverse outcomes in DLBCL. a Sirt6 was upregulated in DLBCL (n = 163) in contrast to normal samples based on the GSE83632 data set. b Kaplan-Meier survival curve analysis indicated that high Sirt6 expression in DLBCL appeared to be correlated with shorter overall survival based on analysis of the GSE32918 data set (n = 249, p = 0.0023). c Compared to samples of RHL, expression levels of Sirt6 were significantly increased in DLBCL tissues. Upper: bar = 50 μm, lower: bar = 100 μm. d Kaplan–Meier survival curve analysis indicated that high Sirt6 expression in DLBCL appeared to be correlated with shorter overall survival based on analysis of our IHC data (n = 60, p = 0.039). e Aberrantly raised Sirt6 mRNA expression levels were observed in DLBCL cell lines (LY1, LY8, Val, LY3) compared to those in control cells (N1, N2, N3). f Western blotting assays showed high expression of Sirt6 protein in DLBCL cells. ***p < 0.001

Back to article page